Laura Rodriguez Pons

Laura Rodriguez Pons

Auto-generated profile, based on publicly available information

Laura Rodriguez Pons

Pulmonology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
KCKarina Portillo Carroz
Karina Portillo Carroz
BUBlanca Urrutia-Royo
Blanca Urrutia-Royo
TMToni Marin
Toni Marin
LPLaura Rodriguez Pons
Laura Rodriguez Pons
PMPaloma Millán-Billi
Paloma Millán-Billi
OMOnofre Moran-Mendoza
Onofre Moran-Mendoza
Background and Objective: Interstitial lung diseases (ILDs) encompass over 200 entities. Among them, fibrosing lung diseases, have recently generated special interest due to the emerging therapies for their management. However, it is important to deepen our knowledge of other less prevalent ILD, since many of them are associated with a poor prognosis. This narrative review aims to provide a practical and up-to-date description of some poorly recognized ILD. It covers rare idiopathic interstitial pneumonias and their histologic patterns, genetic disorders with interstitial lung involvement (Hermansky-Pudlak syndrome), and ILD associated with benign proliferation of pulmonary lymphoid tissue, namely follicular bronchiolitis and granulomatous-lymphocytic interstitial lung disease. Methods: Electronic searches of PubMed and Google Scholar using specific keywords were conducted. Articles underwent screening for relevance, covering review articles, meta-analyses, systematic reviews, case series, prospective studies, society guidelines, editorials in peer-reviewed journals; scientific books on the subject. The data included was limited to English and Spanish publications. Key Content and Findings: Despite the low prevalence of these diseases, the increased recognition of radiological patterns, pathological features, and diagnostic procedures, have permitted their better characterization. This review highlights epidemiology, clinical presentation, diagnosis, natural history, and treatment. Conclusions: Lesser-studied ILD represent a diagnostic and therapeutic challenge and can be frequently misdiagnosed. Also, due to the lack of randomized controlled trials, there are no well-established therapeutic options. Further studies or registries are needed to improve accurate diagnosis and management.

1 October 2026 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
FGFilipe Gonçalves-Carvalho
Filipe Gonçalves-Carvalho
SQSara Quero
Sara Quero
IGIgnasi Garcia-Olive
Ignasi Garcia-Olive
LRLaura Rodríguez
Laura Rodríguez
ESTHER BARREIROESTHER BARREIRO
ESTHER BARREIRO
AMAlicia Marín
Alicia Marín
Background: Airway microbiome composition in bronchiectasis extends beyond conventional microbiology, but its clinical implications remain unclear. Aim: This study evaluated the airway bacteriome and mycobiome in bronchiectasis, examining their associations with clinical characteristics, inflammatory patterns and disease aetiology. Methods: This study reports the pre-specified baseline cross-sectional analysis from a prospective multicentre cohort of 153 adults with non-CF bronchiectasis studied during clinical stability. Airway bacterial and fungal communities were characterised using 16S rRNA (V3–V4) and ITS2 sequencing. Samples were stratified by dominant bacterial genus, associations with clinical features, inflammatory biomarkers and aetiological subgroups were assessed. LEfSe was used as an exploratory method to identify bacterial genera with differential relative abundance across dominance groups. Results: Pseudomonas -dominant bacteriomes showed the lowest α-diversity, and the strongest associations with disease severity, including poorer lung function, higher BSI scores and elevated sputum inflammatory markers. Haemophilus -dominant communities also correlated with reduced diversity and airway inflammation, although were associated with milder clinical severity compared with Pseudomonas . In contrast, Streptococcus -dominant bacteriomes demonstrated the highest bacterial diversity, enrichment of commensal genera, lower inflammatory marker levels and more favourable clinical features. The mycobiome also contributed to airway ecology: Ascomycota abundance correlated with higher bacterial diversity and lower inflammatory biomarker levels, whereas Basidiomycota dominance was associated with reduced diversity and a pro-inflammatory pattern. Distinct taxa were associated with specific aetiologies, including Rothia and Porphyromonas in immunodeficiencies and Staphylococcus in primary ciliary dyskinesia. Conclusion: Airway microbiome dominance is associated with distinct clinical characteristics and inflammatory patterns in bronchiectasis. In a well-characterised multicentre cohort, integration of bacteriome and mycobiome data with inflammatory and remodelling markers provides external validation of previous observations and may contribute to a better characterisation of disease heterogeneity.